In this single-arm trial, the median overall survival (OS) observed was 4.0 months (95% CI: 2.5-7.2) among all 64 adults in the primary efficacy analysis based on the Kaplan-Meier estimate. The median ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Good day, everyone, and welcome to the Syndax First Quarter 2025 ...

There is a consistent need from researchers to manufacture a cGMP virus to support the advancement of gene therapies.

A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and ...

Curis, Inc. Q1 2025 updates show progress in CNS lymphoma & AML trials with emavusertib, boosted by financial discipline & strategic expansion.

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Apr. 25, 2025 — Chimpanzee naive pluripotent stem cells (PSCs) can now be grown in cellular cultures, reveals a recent study. They successfully created chimpanzee early embryo models ...

Revumenib was previously granted Orphan Drug Designation for the treatment of AML, ALL and acute leukemias of ambiguous lineage (ALAL) by the U.S. FDA and for the treatment of AML by the European ...